Revenue segments as reported by the company.

Product revenue

Service and other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Sales, general and administrative

Merger-related expenses

Change in fair value of contingent consideration

Amortization of acquired intangible assets

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pacific Biosciences of California

Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. It operates through the following geographical segments: North America, Europe, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pacific Biosciences sees strong Revio demand driving revenue growth

PACB reported a revenue decrease in Q4 2022 but saw strong customer interest in the Revio system, driving revenue growth expectations for 2023. The company is strategically focused on Revio adoption, Onso's performance, and managing market challenges. Opportunities exist in scaling manufacturing capacity, expanding customer reach, and leveraging high demand for Revio and Onso.

PacBio surpasses revenue expectations with strong Revio demand

PacBio's Q1 2023 performance exceeded expectations with record revenue and strong Revio demand, setting up growth opportunities.
While facing challenges in gross margin and operating expenses, PacBio's innovative approach and broad market appeal position it well for the future.
With a focus on margin expansion, consumables growth, and balancing product demand, PacBio aims for sustained profitability and market leadership.
The successful Revio launch and strong China business highlight PacBio's potential for long-term growth and market impact.

PacBio reports record Q2 revenue, eyes market gains and gross margin improvements

PacBio's Q2 performance marked by record revenue, strategic acquisitions, and strong guidance update for 2023 growth.
Focus on Revio system adoption, consumables pull-through, and backlog reduction positions the company for sustained success.
Challenges include market competition, sustaining growth post-upgrade cycle, and addressing validation issues for new products.
Opportunities lie in market shifts towards long reads, improving gross margins through product mix changes, and expanding market access.

PacBio reports record Q3 revenue growth and strategic advancements

PacBio delivered robust performance in Q3, achieving record revenue and strong growth, driven by increased demand for Revio systems and consumables.
While facing challenges such as budget constraints and macroeconomic uncertainties, PacBio's strategic strengths lie in product innovation, market expansion, and financial stability.
Opportunities abound in collaborations, technology enhancements, and market growth, positioning PacBio for continued success and leadership in the genomics industry.
With a positive outlook for future revenue growth, PacBio remains focused on driving innovation, expanding its customer base, and navigating market challenges.

Pacific Biosciences reports robust 2023 performance and eyes growth

PACB had a strong 2023 with revenue growth and successful Revio adoption, despite challenges in China impacting placements.
New kits, software updates, and positive customer feedback on platforms indicate market acceptance and drive customer enthusiasm.
Strategic priorities for 2024 focus on expansion, technology development, and revenue growth, with opportunities in clinical markets and alternative business models.

Pacific Biosciences reports Q2 revenue below expectations, focuses on growth

Pacific Biosciences of California reported Q2 revenue below expectations but showed strength in consumable revenue growth. The company is focused on reducing expenses, improving cash burn, and driving instrument placements. Despite challenges, there are opportunities for growth through attractive deals and positive outlook for consumables.
The company's performance in Q2 reflects ongoing efforts to improve margins and drive revenue growth. Challenges in revenue expectations and headwinds are being addressed through cost reductions and strategic initiatives. Pacific Biosciences remains confident in its progress and future prospects.
With a focus on cost reduction, revenue improvement, and strategic priorities, Pacific Biosciences aims to achieve cash flow positivity by 2026. The company's strengths lie in consumable revenue growth, successful marketing events, and confidence in its product pipeline. Challenges in revenue and cash flow are being managed with opportunities for growth through instrument placements and deals.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. It operates through the following geographical segments: America, Europe, Middle East, and Africa, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.

PacBio's (PACB) research collaboration with Google will likely enhance its HiFi Sequencing technology to extract greater value from genomic data.

PacBio (PACB) to Leverage Google's Deep Learning Technologies

PacBio's (PACB) solid fourth-quarter results are likely to have been boosted by strong segmental performances and robust placement of Sequel systems.

PacBio (PACB) Reports Impressive Preliminary Q4, FY21 Revenues

Adagio Therapeutics

BioNTech SE

Novavax

Vertex Pharmaceuticals

Could these biotech stocks be poised for gains in 2022?

5 Top Biotech Stocks To Watch In January 2022

Industry Veteran Will Lead Company's Commercial Growth Strategy in Americas Region Industry Veteran Will Lead Company's Commercial Growth Strategy in Americas Region

PacBio Names Lara Toerien as Vice President and General Manager for the Americas

Preliminary fourth-quarter results reached a record high but didn't quite meet expectations.

Why Shares of Pacific Biosciences of California Are Under Pressure Today

TechnipFMC

Investors are trying to get on an even keel after a rough start to 2022.

These 2 Stocks Could Threaten Tuesday's Market Bounce

New collaboration builds on existing relationship between the two companies to develop desktop systems for the clinical market in China

PacBio and Berry Genomics Announce Collaboration to Bring Long Read Desktop Sequencing Instrument to the Clinical Market in China

Pilot project designed to demonstrate the power of HiFi sequencing to effectively and efficiently identify novel variants following short-read genome sequencing Pilot project designed to demonstrate the power of HiFi sequencing to effectively and efficiently identify novel variants following short-read genome sequencing

PacBio Announces Collaboration with Genomics England to Sequence Biobanked Rare Disease Samples Using HiFi Sequencing Technology

Initial proof-of-concept work suggests strong potential to further improve PacBio's highly accurate HiFi Sequencing with Google deep learning technologies Initial proof-of-concept work suggests strong potential to further improve PacBio's highly accurate HiFi Sequencing with Google deep learning technologies

PacBio and Google Collaborate to Use Machine Learning to Optimize Long-Read Sequencing Data Analysis

MENLO PARK, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing platforms, today announced unaudited preliminary revenue of approximately $36.0 million for its fourth quarter ended December 31, 2021. The Company's full financial results for the fourth quarter and the fiscal year ended December 31, 2021, are not yet available.

PacBio Announces Record Preliminary Fourth Quarter 2021 Revenue, New Sequencing Kits and Workflows, and Expanded Collaborations

PacBio's (PACB) sequencing system enhances Radboudumc's SMRT sequencing capability through the addition of two new PacBio Sequel IIe systems.

PacBio's (PACB) Sequel IIe Boosts Radboudumc's Sequencing Ability

Added whole genome sequencing capacity enables the SOLVE-RD research program to significantly increase sample throughput Added whole genome sequencing capacity enables the SOLVE-RD research program to significantly increase sample throughput

Radboud University Medical Center Increases HiFi Sequencing Capacity with PacBio's Sequel IIe

PacBio's (PACB) recent partnership with Care4Rare, with regard to a study, has the potential to enhance rare disease diagnosis within Canada.

PacBio (PACB) Ties Up to Boost Rare Disease Diagnosis in Canada

PacBio's Sequel IIe devices will support genomic researchers around the world PacBio's Sequel IIe devices will support genomic researchers around the world

Azenta Life Sciences Expands Fleet of PacBio HiFi Sequencing Systems

The study will evaluate the impact of high-resolution genomes generated on PacBio technology in studying unsolved rare disease cases The study will evaluate the impact of high-resolution genomes generated on PacBio technology in studying unsolved rare disease cases

PacBio and Care4Rare Consortium Collaborate on Rare Disease Research Study

MENLO PARK, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- PacBio announced today that its executives will be speaking virtually at the following investor conference:

PacBio to Present at Upcoming Investor Conference

PacBio's (PACB) latest surveillance kit is expected to aid public health entities to better answer critical questions about Omicron and its impacts.

PacBio's (PACB) New Surveillance Kit Successful Against Omicron

HiFiViral Solution helps to accelerate understanding of the Omicron variant, providing information that is important to public health response HiFiViral Solution helps to accelerate understanding of the Omicron variant, providing information that is important to public health response

PacBio's New HiFiViral Surveillance Kit Performance is Not Impacted by Omicron Mutations, Delivering Complete SARS-CoV-2 Genomes for All Circulating Variants

PacBio's (PACB) latest research collaboration is expected to identify the causes behind rare diseases and provide more effective treatments.

PacBio (PACB)-UCLA Health Tie Up for Rare Diseases' WGS Research

Collaboration aims to identify variants not easily detectible by short-read sequencing, increasing diagnostic yield in rare disease patients Collaboration aims to identify variants not easily detectible by short-read sequencing, increasing diagnostic yield in rare disease patients

PacBio and UCLA Health Announce Research Collaboration for Whole Genome Sequencing in Rare Diseases

Strategic hire will expand Company's commercial presence in key geography Strategic hire will expand Company's commercial presence in key geography

PacBio Names Jason Kang as Vice President and General Manager for Asia-Pacific Region

PacBio's (PACB) recent partnership with ARUP Laboratories, with regard to a study, has the potential to enhance rare disease diagnosis.

PacBio's (PACB) Collaboration to Boost Rare Disease Diagnosis

PacBio's (PACB) newly launched end-to-end solution is likely to help in the fight against infectious diseases and bolster public health response to pathogen threats.

PacBio's (PACB) New Solution to Boost Public Health Protection

Whole genome HiFi sequencing will be used on unexplained rare disease cases to evaluate if it can identify variants not readily detectable by short-read sequencing Whole genome HiFi sequencing will be used on unexplained rare disease cases to evaluate if it can identify variants not readily detectable by short-read sequencing

PacBio and ARUP Laboratories Collaborate in a Study to Improve Rare Disease Diagnosis

Robust SARS-CoV-2 sequencing kit and upgraded microbial whole genome assembly workflow enable public health laboratories to scale pathogen surveillance programs Robust SARS-CoV-2 sequencing kit and upgraded microbial whole genome assembly workflow enable public health laboratories to scale pathogen surveillance programs

PacBio Launches HiFiViral SARS-CoV-2 Kit and Microbial Whole Genome Sequencing Enhancements to Combat Infectious Disease and Strengthen Public Health Response to Pathogen Threats

News for Pacific Biosciences of California Stock (PACB)